Tabor Asset Management LP Makes New Investment in Inhibrx Biosciences, Inc. (NASDAQ:INBX)

Tabor Asset Management LP acquired a new position in shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 36,195 shares of the company's stock, valued at approximately $506,000. Tabor Asset Management LP owned 0.25% of Inhibrx Biosciences at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. Sanofi acquired a new position in Inhibrx Biosciences during the 4th quarter valued at $17,832,000. Walleye Capital LLC acquired a new position in shares of Inhibrx Biosciences in the 4th quarter valued at $8,932,000. Slotnik Capital LLC acquired a new position in shares of Inhibrx Biosciences in the 4th quarter valued at $5,975,000. Millennium Management LLC acquired a new position in shares of Inhibrx Biosciences in the 4th quarter valued at $3,979,000. Finally, Geode Capital Management LLC acquired a new position in shares of Inhibrx Biosciences in the 4th quarter valued at $3,930,000. 82.46% of the stock is owned by institutional investors.

Inhibrx Biosciences Price Performance

Shares of INBX traded down $0.98 during trading hours on Friday, hitting $22.09. The stock had a trading volume of 51,783 shares, compared to its average volume of 105,260. The company's fifty day moving average is $16.37 and its two-hundred day moving average is $14.12. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.12 and a quick ratio of 5.12. Inhibrx Biosciences, Inc. has a 52 week low of $10.80 and a 52 week high of $24.75. The stock has a market capitalization of $319.86 million, a price-to-earnings ratio of 0.19 and a beta of -0.04.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($2.55) by ($0.25). On average, analysts anticipate that Inhibrx Biosciences, Inc. will post 104.88 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx Biosciences in a research note on Thursday, May 15th.

About Inhibrx Biosciences

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.